Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553800 · ClinicalTrials.gov registry record · Phase 2
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00553800 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT00553800, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
Interventions
- DRUG bevacizumab
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-07-05 |
| Est. Completion | 2011-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553800
The ClinicalTrials.gov registry entry for NCT00553800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00553800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00553800 about?
NCT00553800 is a clinical study titled "Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer". This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
What is the current status of trial NCT00553800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-07-05. Estimated completion is 2011-06-01.
What interventions are being tested in trial NCT00553800?
The interventions under investigation include: bevacizumab (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00553800?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.